Enavate Sciences GP, LLC

CIK: 0001953107Latest portfolio: $506.8M · Q4 2025

Holdings

7

Total Value

$506.8M

New Positions

0

Closed Positions

0

Top Holdings

#StockSharesValue% PortfolioChangeType
1
ZBIOZENAS BIOPHARMA INC
3,919,159$142.3M28.08%+158K
2
IMNMIMMUNOME INC
4,768,583$102.4M20.21%
3
SIONSIONNA THERAPEUTICS INC
2,478,030$101.9M20.12%
4
UPBUPSTREAM BIO INC
2,459,703$66.8M13.18%
5
CMPXCOMPASS THERAPEUTICS INC
7,788,150$41.8M8.25%
6
BBOTBRIDGEBIO ONCOLOGY THERAPEUT
2,626,946$32.9M6.49%
7
CAMPCAMP4 THERAPEUTICS CORP
3,035,825$18.6M3.67%-749,977

Sector Breakdown

Healthcare100.0% ($1.4230410242910194e+28T)

Filing History

QuarterFiling DatePortfolio ValueHoldings
Q4 2025Feb 17, 2026$506.8M7
Q3 2025Nov 14, 2025$327.5B7
Q2 2025Aug 14, 2025$176.5B6
Q1 2025May 15, 2025$132.7B6
Q4 2024Feb 14, 2025$139.2B5

Fund Information

CIK0001953107
Most Recent FilingFeb 17, 2026
Number of Filings5

Enavate Sciences GP, LLC is an institutional investment manager that files 13F reports with the SEC. As of the Q4 2025 filing, the fund reported a portfolio valued at $506.8M across 7 holdings. The largest position is ZENAS BIOPHARMA INC (ZBIO), representing 28.1% of the portfolio. Compared to the previous quarter, the fund opened 0 new positions and closed 0 positions. 13F filings are required quarterly disclosures that provide transparency into the holdings of institutional investment managers with at least $100 million in qualifying assets.